Liraglutide for PCOS: Evidence, Eligibility, Coverage

Liraglutide is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SCALE Obesity and Prediabetes, people on Saxenda lost 7.4% of body weight on average, vs 3% on placebo.

Brands: Victoza and Saxenda
Best result (SCALE Obesity and Prediabetes): 7.4% weight loss

Saxenda basics

How long it remains in your body

Its half-life is about 13 hours. Once 13 h pass, half the dose is gone. At 2.7 d, or five half-lives, about 3% is left.

Amount of weight lost in the main trial

SCALE Obesity and Prediabetes, 56-week study: 7.4% of body weight lost, versus 3% on placebo.

Where the warning comes from: FDA label (DailyMed).

Who qualifies?

Which patients qualify for liraglutide?
Who sets the rule	Who qualifies
Victoza	It lowers blood sugar when used with diet and exercise, in adults and children age 10 and up with type 2 diabetes.
Victoza	It lowers the risk of heart attack, stroke, or heart-related death for adults with type 2 diabetes plus heart disease.
Saxenda	Diet and activity are used to lose weight and to keep it off over the long term. This applies to children and adults 12 and older (over 60 kg) who have obesity, and to adults with overweight plus a weight-related condition.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	first comes a diet and activity program lasting 6 months

Sources: FDA label (DailyMed) 1, 2, and aetna.com.

Trial results for PCOS

None of these trials enrolled only polycystic ovary syndrome (PCOS); the people studied were adults with obesity or overweight but without type 2 diabetes.

Liraglutide trials: polycystic ovary syndrome (PCOS)
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SCALE Obesity and Prediabetes	Saxenda	Adults with obesity or overweight but without type 2 diabetes	56 weeks	3,731	7.4% weight loss	3% on placebo

Where the trial data come from: SCALE Obesity and Prediabetes (FDA label (DailyMed)).

What is different for PCOS?

What the label says about liraglutide when you have polycystic ovary syndrome (PCOS)
What changes	What the label says	Labels
Hypoglycemia	Combining liraglutide with insulin or a sulfonylurea makes low blood sugar more likely, so the doses of those medicines may need to be lowered.	All of them

According to the FDA labels: FDA DailyMed label.

According to the label warnings: FDA DailyMed label.

Coverage for PCOS

A GLP-1 used only for weight loss is not covered by Medicare Part D.

When Medicaid covers weight-loss GLP-1s, it usually requires prior authorization.

Sources: humana.com, KFF.

Alternatives for PCOS

GLP-1 class medicines and polycystic ovary syndrome (PCOS)
Medicine	For PCOS	How it is taken	Trial result
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed